Next Article in Journal
Ultrastructural Analysis of Prune Dwarf Virus Intercellular Transport and Pathogenesis
Next Article in Special Issue
Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
Previous Article in Journal
Regulation of Energy Expenditure and Brown/Beige Thermogenic Activity by Interleukins: New Roles for Old Actors
Previous Article in Special Issue
Diagnostic and Prognostic Implications of FGFR3high/Ki67high Papillary Bladder Cancers
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview

Circulating Tumour DNA in Muscle-Invasive Bladder Cancer

1
Division of Radiotherapy & Imaging, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
2
Academic Urology Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
3
Research Department of Oncology, UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6DD, UK
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(9), 2568; https://doi.org/10.3390/ijms19092568
Received: 31 July 2018 / Revised: 25 August 2018 / Accepted: 27 August 2018 / Published: 29 August 2018
  |  
PDF [220 KB, uploaded 29 August 2018]

Abstract

Circulating tumour DNA (ctDNA) is an attractive tool in cancer research, offering many advantages over tissue samples obtained using traditional biopsy methods. There has been increasing interest in its application to muscle-invasive bladder cancer (MIBC), which is recognised to be a heterogeneous disease with overall poor prognosis. Using a range of platforms, studies have shown that ctDNA is detectable in MIBC and may be a useful biomarker in monitoring disease status and guiding treatment decisions in MIBC patients. Currently, with no such predictive or prognostic biomarkers in clinical practice to guide treatment strategy, there is a real unmet need for a personalised medicine approach in MIBC, and ctDNA offers an exciting avenue through which to pursue this goal. In this article, we present an overview of work to date on ctDNA in MIBC, and discuss the inherent challenges present as well as the potential future clinical applications. View Full-Text
Keywords: circulating tumour DNA (ctDNA); muscle-invasive bladder cancer (MIBC); biomarker circulating tumour DNA (ctDNA); muscle-invasive bladder cancer (MIBC); biomarker
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed
Printed Edition Available!
A printed edition of this Special Issue is available here.

Share & Cite This Article

MDPI and ACS Style

Tan, M.P.; Attard, G.; Huddart, R.A. Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. Int. J. Mol. Sci. 2018, 19, 2568.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top